Minnesota Opioid Prescribing Guidelines

Event Date:
Monday, February 4, 2019 (All day) to Friday, February 4, 2022 (All day)

Activity Description

The Minnesota legislature authorized the Opioid Prescribing Improvement Program in 2015, which in turn called for the formation of a group of experts to recommend statewide prescribing guidelines.  On March 30, 2018, Minnesota Opioid Prescribing Guidelines, First Edition was distributed by the Minnesota Departments of Human Services and Health. This educational activity is a collaboration of the University of Minnesota and the Department of Human Services to provide physicians, nurses and pharmacists with an overview of the six essential guidelines, supplemental tools for assessment and pain management, as well as a series of case-based questions to examine opioid prescription and pain management.

Content Outline

All podcast course information presented is found verbatim within the guidelines document and has not been modified by the University of Minnesota School, faculty, or our presenters. Learners who participate in this activity must listen to the podcast, a recorded narration of the Minnesota Opioid Prescribing Guidelines, First Edition 2018. A pdf copy is also made available. Following their review of the Guidelines, learners participate in a series of case-based questions.

The Minnesota Opioid Prescribing Guidelines, First Edition 2018 includesthe following sections:
•Patient Safety Recommendations: All Pain Phases
•Biopsychosocial and Risk Assessment
•Non-opioid and Non-pharmacological Pain Management
•Opioid Prescribing for Acute Pain (0-4 days following an acute event)
•Opioid Prescribing for Post-Acute Pain (5 to 45 days following an acute event)
•Opioid Prescribing for Chronic Pain
•Tapering or Discontinuing Opioid Therapy
•Women of Childbearing Age

Learning Objectives

After participating in this activity, you should be better able to:

  • Define the three pain phases used in the MN Opioid Prescribing Guidelines.
  • Identify the risk factors associated with the progression from opioid use for acute pain to long-term opioid use.
  • Define the recommended opioid dose limits for acute pain, post-acute pain, and chronic pain.

Method of Participation

Learners can engage in the content at no cost. The Minnesota Opioid Prescribing Guidelines, First Edition are available in recorded audio format and in printed format. At the conclusion of the case-based questions, learners will have the option to claim credit for their participation in the activity.  The cost to claim credit is $25.00.

Completing this online activity for credit consists of five steps:

  1. Access the online activity to review the audio recordings and/or print copy of the Minnesota Opioid Prescribing Guidelines, Frist edition, 2018
  2. Within the online activity, compete the case-based quiz
  3. Complete the activity evaluation form
  4. Submit your registration and payment for the activity
  5. Receive your statement of participation within 4-6 weeks of completing these steps

Estimated time to complete: 2 hours

Release Date: February 4, 2019
Content Valid Through: February 4, 2022

This activity was developed prior to the 2019 legislative session when the Minnesota legislature passed Minnesota Statutes § 214.12, subd.6 requiring licensees with authority to prescribe controlled substances to obtain at least two hours of education credit on best practices in prescribing opioids and controlled substance. This activity was not developed to satisfy the mandated CE requirement.


In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statements

American Medical Association (AMA)
The University of Minnesota, Interprofessional Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)
This activity is awarded up to 2.0 ANCC contact hours.

Accreditation Council for Pharmacy Education (ACPE)
This activity is eligible for up to 2.0 ACPE contact hours. Information from the participant verification form (which includes your NABP # and month and date of birth) will be uploaded to The Monitor within four weeks of your completion of the activity. 

Other Healthcare Professionals
Other healthcare professionals who participate in this CE activity may submit their statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Disclosure Policy

It is the policy of the University Of Minnesota Office Of Continuing Professional Development to ensure balance, independence, objectivity and scientific rigor in all of its sponsored educational activities. All individuals (including spouse/partner) who have influence over activity content are required to disclose to the learners any financial relationships with a commercial interest related to the subject matter of this activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by or used on, patients.  Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest.  Specific disclosure information for each presenter, activity director, and planning committee member will be shared with the learner prior to the presenter's presentation.  Persons who fail to complete and sign this form in advance of the activity are not eligible to be involved in this activity.

Planning Committee and Authors

The individuals involved in this activity did not indicate any financial relationships and do not intend to discuss off-label/investigative use of a commercial product or device.

  • Mark Rosenberg, MD, Vice Dean for Education, University of Minnesota Medical School

  • Jeff Schiff MD, MBA; Medical Director, Minnesota Department of Human Services

  • Sarah Rinn, MPH; Minnesota Department of Human Services

  • Mary Mescher Benbenek Ph.D., R.N., C.P.N.P., C.F.N.P.; Clinical Associate Professor, FNP Program Coordinator, University of  Minnesota School of Nursing

  • Heather Blue, PharmD, BCPS, BCGP; Assistant Professor, University of Minnesota College of Pharmacy, Duluth

  • Jodi Brenden Amir, Accreditation Specialist, Office of Continuing Professional Development, University of Minnesota

  • Mia Mullins, Director, Office of Continuing Professional Development, University of Minnesota (former)

  • Hannah Holzschuh, Operations Manager, Office of Continuing Professional Development, University of Minnesota


For feedback, questions or technical concerns, contact the Office of Continuing Professional Development at 612-626-7600 or cme@umn.edu.


The University of Minnesota wishes to acknowlege the following individuals: 

Opioid Prescribing Work Group Members
Julie Cunningham, PharmD, BCPP; Senator Chris Eaton, RN; Tiffany Elton, PharmD, NCPS; Dana Farley, MS; Rebekah Forrest, RN, CNP; Ifeyinwa Nneka Igwe, MD; Bradly Johnson, MD; Chris Johnson, MD – OPWG Chair; Ernest Lampe, MD; Matthew Lewis, MD (not practicing); Peter Marshall, PharmD; Murray McAllister, PsyD, LP; Richard Nadeau, DDS, MPH; Mary Beth Reinke, PharmD, MSA; Charles Reznikoff, MD; Jeffrey Schiff, MD, MBA; Detective Charles Strack; Lindsey Thomas, MD

Department of Human Services
Assistant Commissioner Nathan Moracco; Jeff Schiff, MD, MBA; Sarah Rinn, MPH